Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.62 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.62 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.62 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.62 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.62 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.62 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.62 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.62 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.62 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.62 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.62 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.62 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.62 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.62 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.62 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863030 | 0.98 | SETD7 (0.68) | SETD7MEN1LMNAMAPTPMP22 | |
| SCHEMBL6803898 | 0.90 | SETD7 (0.71) | SETD7MEN1LMNAMAPTPMP22 | |
| Hydrochloric Acid SCHEMBL7212508 | 0.85 | SETD7 (0.77) | SETD7MEN1LMNAMAPTPMP22 | |
| SCHEMBL9455504 | 0.83 | SETD7 (0.68) | SETD7MEN1LMNAMAPTPMP22 | |
| Hydrochloric Acid SCHEMBL7212638 | 0.82 | SETD7 (0.62) | SETD7MEN1LMNAMAPTPMP22 | |
| SCHEMBL6808721 | 0.81 | SETD7 (0.65) | SETD7MEN1LMNAMAPTPMP22 | |
| SCHEMBL9034546 | 0.81 | SETD7 (0.64) | SETD7MEN1LMNAMAPTPMP22 | |
| SCHEMBL7218739 | 0.81 | SETD7 (0.75) | SETD7MEN1LMNAMAPTPMP22 | |
| Hydrochloric Acid SCHEMBL9034037 | 0.80 | SETD7 (0.97) | SETD7MEN1LMNAMAPTPMP22 | |
| Hydrochloric Acid SCHEMBL7213774 | 0.80 | SETD7 (0.97) | SETD7MEN1LMNAMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063701-A1 | Piperidine derivatives and anti-platelet agents containing the same | AJINOMOTO CO., INC (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-0770602-B1 | Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same | AJINOMOTO KK (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-20020147195-A1 | Piperidine derivatives and anti-platelet agents containing the same | AJINOMOTO CO., INC. (JP) | 2002-10-10 | — | — | US | disclosed |
| US-6444821-B2 | HUMIDITY-CONTROLLING THE CRYSTALS OF N-(2-(4-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-PIPERIDINO)ETHYL)-1-FORMYL-4 -PIPERIDINECARBOXAMIDE HYDROCHLORIDE ANHYDRIDE | AJINOMOTO CO., INC. (JP) | 2002-09-03 | — | — | US | disclosed |
| US-20020019533-A1 | PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME | MAKINO SHINGO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-20010056102-A1 | Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same | AJINOMOTO CO., INC. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-0682015-B1 | Piperidine derivates and anti-platelet agents containing the same | AJINOMOTO KK (JP) | 2001-08-22 | — | — | EP | disclosed |
| EP-1103544-A2 | Piperidine derivatives and antiplatelet agents containing the same | Ajinomoto Co., Inc. (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-6232323-B1 | N-(2-(4-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-PIPERIDINO)ETHY L)-1-FORMYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE TRIHYDRATE | AJINOMOTO CO., INC. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6184233-B1 | CRYSTALS HAVING STORAGE STABILITY, ORAL ABSORPTION, SOLUBILITY; HYPOTENSIVE AGENTS, PLATELET AGGLUTINATION CONTROL AGENTS | AJINOMOTO CO., INC. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0770602-A2 | Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same | Ajinomoto Co., Inc. (JP) | 1997-05-02 | — | — | EP | disclosed |
| EP-0682015-A1 | Piperidine derivates and anti-platelet agents containing the same | Ajinomoto Co., Inc. (JP) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056102-A1 | Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same | DCTD, DDC, QDPR | DRD3 157/4885HTR1A 1260/4885DRD2 80/4885 |
| US-20020019533-A1 | PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME | HTR2A, PDGFRA, PDGFRB | DRD3 164/4885HTR1A 5/4885DRD2 37/4885 |
| US-20020147195-A1 | Piperidine derivatives and anti-platelet agents containing the same | HTR2A, PDGFRA, PDGFRB | DRD3 164/4885HTR1A 5/4885DRD2 37/4885 |
| US-20040063701-A1 | Piperidine derivatives and anti-platelet agents containing the same | HTR2A, PDGFRA, PDGFRB | DRD3 164/4885HTR1A 5/4885DRD2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.